TuisNVAX • NASDAQ
add
Novavax Inc
Vorige sluiting
$7,51
Dagwisseling
$7,51 - $7,68
Jaarwisseling
$5,01 - $11,50
Markkapitalisasie
1,23Â mjd USD
Gemiddelde volume
4,24Â m
P/V-verhouding
3,34
Dividend-opbrengs
-
PrimĂŞre beurs
NASDAQ
In die nuus
Meer oor
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company's first and only commercial product is the Novavax COVID-19 vaccine. The company is also developing vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria.
Novavax also develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine. Wikipedia
Gestig
1987
Webwerf
Werknemers
952